Patents Assigned to RF THERAPEUTICS INC.
  • Targeted contrast agents comprising a hydrazide functional group
    Patent number: 10286090
    Abstract: Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes a hydrazide functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal-complexable portion of the contrast agent. The portion that is not bound to a metal ion localizes the contrast agent to necrotic tissue in the subject.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: May 14, 2019
    Assignee: RF Therapeutics Inc.
    Inventors: Zhang Jidong, Curry Ken
  • TARGETED CONTRAST AGENTS AND USES THEREOF
    Publication number: 20140065075
    Abstract: Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes an unchelated aminocarboxylate functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal-complexable portion of the contrast agent. The portion that is not bound to a metal ion is for binding to necrotic tissue in the subject.
    Type: Application
    Filed: April 17, 2012
    Publication date: March 6, 2014
    Applicant: RF THERAPEUTICS INC.
    Inventors: Jidong Zhang, Kenneth Curry